Materiały źródłowe

• #1 Medium-Chain Acyl-CoA Dehydrogenase Deficiency – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560837/

  Mutations in the ACADM gene on chromosome 1p31 are responsible for this disorder. These mutations result in misfolding of the translated protein, leading to decreased or absent function of the MCAD enzyme. The ACADM gene spans 44kb of DNA and has 12 introns. Current data reports 400 different ACADM gene variations, of which 68 different variations have been classified as pathogenic, 82 variations as likely pathogenic, and around 165 variations grouped as „uncertain.” Around 69% of these disease-causing variations are missense mutations. […] The most prevalent mutation is c.985AG, resulting in lysine at position 304 being exchanged for glutamate. Misfolding of the protein subsequently occurs, leading to a complete loss of function. This mutation is the most common mutation in symptomatic patients, seen in up to 80% of the individuals as a homozygous mutation. It may also occur in heterozygosity with other variants, resulting in a milder form of the disease. […] MCADD is an autosomal recessive disorder caused by mutations in the acyl-CoA dehydrogenase medium chain (ACADM) gene.

• #2 Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1424/

  Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency is a disorder of mitochondrial fatty acid beta-oxidation. […] MCAD deficiency is inherited in an autosomal recessive manner. […] The leading 25 amino acids of the precursor protein are cleaved off once the MCAD protein has reached the mitochondria. […] Individuals with MCAD deficiency have reduced mitochondrial MCAD enzyme functioning and cannot convert medium-chain fatty acids (those with 6-10 carbons) into acetyl-CoA for ATP synthesis, ketogenesis, and Krebs (i.e., tricarboxylic acid) cycle use. […] Loss of function.

• #3 Medium-chain acyl-CoA dehydrogenase deficiency – Genomics Education Programme

  http://www.genomicseducation.hee.nhs.uk/documents/medium-chain-acyl-coa-dehydrogenase-deficiency/

  Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is an autosomal recessive disorder of fatty acid oxidation that prevents the conversion of fats to energy via hepatic ketogenesis. This impairs the supply of energy to peripheral tissues, causing a continual reliance on glucose to provide energy. […] MCADD is caused by autosomal recessive variants in the ACADM gene, which encodes the mitochondrial medium-chain acyl-CoA dehydrogenase (MCAD) enzyme. […] The most prevalent variant is c.985AG, which accounts for 80% of cases. […] Other variants, for example, p.Tyr42His (which has an allele frequency of ~6%) are associated with some residual MCAD enzyme activity. However, individuals with this phenotype can still develop life-threatening symptoms in an acute crisis.

• #4 MCAD deficiency – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/mcad-deficiency/symptoms-causes/syc-20353745

  Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency is an inherited disorder that prevents your body from breaking down certain fats and turning them into energy. […] MCAD deficiency is caused by a change in the ACADM gene. The condition is inherited from both parents in an autosomal recessive pattern. This means that both parents are carriers each has one changed gene and one unchanged gene but they don’t have symptoms of the condition. The child with MCAD deficiency inherits two copies of the changed gene one from each parent. […] When you don’t have enough of the MCAD enzyme in your body, certain fats called medium-chain fatty acids can’t be broken down and turned into energy. This leads to low energy and low blood sugar. Also, fatty acids can build up in body tissues and cause damage.

• #5 MCADD

  https://www.nhs.uk/conditions/mcadd/

  MCADD is caused by a fault in the gene that provides the instructions to make an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). […] This genetic fault causes the enzyme to either not work properly or be missing entirely, which means the body cannot fully break down fat to release energy. […] If the body needs to break down fat quickly (for example, if you’re unwell and have not eaten for a while), energy cannot be produced quickly enough to meet the body’s needs and substances created when fat is partially broken down can build up to harmful levels in the body. […] This can lead to serious problems if not treated quickly.

• #6

  https://www.singhealth.com.sg/patient-care/conditions-treatments/medium-chain-acyl-coa-dehydrogenase-deficiency

  MCADD is caused by a mutation in the ACADM gene. This gene gives the body instructions for making an enzyme called medium-chain acyl-CoA dehydrogenase, needed to break down fats into energy. […] MCADD follows a recessive inheritance pattern. This means that a patient with MCADD must have two faulty copies of ACADM to cause features of MCADD. […] Parents who are both carriers of a disease-causing variant in the ACADM gene have a 25% chance of having an offspring with MCADD.

• #7 MCAD Deficiency

  https://my.clevelandclinic.org/health/diseases/21973-mcad-deficiency

  MCAD deficiency is a genetic condition when your body can’t convert certain fats into energy. […] Medium-chain acyl-coenzyme A (acyl-CoA) dehydrogenase (MCAD) deficiency is a condition that prevents your body from turning fats into energy. […] MCAD deficiency affects people who receive a mutated copy of the ACADM gene from their parents. MCAD deficiency is a genetic condition that you inherit when both of your parents carry a copy of the mutated ACADM gene, and you inherit the mutated copy from each of your parents (autosomal recessive). […] A genetic mutation of the ACADM gene causes MCAD deficiency. The ACADM gene tells your body to make medium-chain acyl-CoA dehydrogenase, which is an enzyme responsible for breaking down medium-chain fatty acids. […] Genetic mutations happen randomly and cant be prevented. The genetic mutation of ACADM causes your body to produce fewer enzymes that break down medium-chain fatty acids. […] People acquire MCAD deficiency through an autosomal recessive pattern, which means that your parents (carriers) both passed a mutated gene onto you.

• #8 Medium-chain acyl-CoA dehydrogenase deficiency: MedlinePlus GeneticsLock

  https://medlineplus.gov/genetics/condition/medium-chain-acyl-coa-dehydrogenase-deficiency/

  Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is a condition that prevents the body from converting certain fats to energy, particularly during periods without food (fasting). […] Mutations in the ACADM gene cause MCAD deficiency. This gene provides instructions for making an enzyme called medium-chain acyl-CoA dehydrogenase, which is required to break down (metabolize) a group of fats called medium-chain fatty acids. […] Mutations in the ACADM gene lead to a shortage (deficiency) of the MCAD enzyme within cells. Without sufficient amounts of this enzyme, medium-chain fatty acids are not metabolized properly. […] This abnormal buildup causes the other signs and symptoms of MCAD deficiency.

• #9

  https://111.wales.nhs.uk/encyclopaedia/m/article/mcadd/

  MCADD is caused by a fault in the gene that provides the instructions to make an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). […] This genetic fault causes the enzyme to either not work properly or be missing entirely, which means the body cannot fully break down fat to release energy. […] If the body needs to break down fat quickly (for example, if you’re unwell and have not eaten for a while), energy cannot be produced quickly enough to meet the body’s needs and substances created when fat is partially broken down can build up to harmful levels in the body. […] A child will only be born with MCADD if they inherit a copy of the faulty gene that causes it from both of their parents. […] The parents will not normally have the condition themselves because they usually only have one copy of the faulty gene each. This is known as being a „carrier”.

• #10 Medium Chain acyl-CoA Dehydrogenase Deficiency – Metabolic Support UKAccessibility ToolsIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://metabolicsupportuk.org/condition/medium-chain-acyl-coa-dehydrogenase-deficiency/

  This condition is grouped with the defects known as Fatty Acid Oxidation Disorders (FOD’s). […] In MCADD, the fat is only partially broken down and therefore your body can not make enough energy quick enough for your body to use it. […] MCADD can only be passed on to a child if both parents have a copy of the faulty gene. This is called autosomal recessive inheritance. […] If both parents are carriers, their child has a one in four (25%) chance of inheriting the disorder, and a one in two chance (50%) of being a carrier.

• #11 Understanding MCAD Deficiency: Symptoms, Causes, and What You Need to Know

  https://tap.health/mcad-deficiency-symptoms/

  MCAD deficiency is caused by a genetic mutation that affects the body’s ability to break down medium-chain fatty acids, a vital energy source. This genetic defect is inherited in an autosomal recessive pattern, meaning both parents must carry the mutated gene for a child to inherit the condition. […] Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is a genetic disorder impacting the body’s ability to break down certain fats for energy. While the exact cause is a genetic mutation inherited from parents, understanding the risk factors is crucial, especially in regions like India and other tropical countries. […] MCAD deficiency is an autosomal recessive disorder. This means that both parents must carry the faulty gene for a child to inherit the condition. If both parents are carriers, there’s a 25% chance with each pregnancy that their child will inherit the condition. Family history is therefore a significant risk factor.

• #12 MCAD deficiency

  https://www.mymlc.com/health-information/diseases-and-conditions/m/mcad-deficiency/

  Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an inherited disorder that prevents your body from breaking down certain fats and converting them into energy. […] When you don’t have enough of the MCAD enzyme in your body, certain fats called medium-chain fatty acids can’t be broken down and converted to energy. This results in hypoglycemia and low energy. Also, fatty acids can build up in body tissues and cause damage to the liver and brain. […] MCAD deficiency is inherited from both parents. Though both parents are carriers — each one has an abnormal gene — they typically don’t have symptoms of the condition. The affected child inherits two copies of the abnormal gene — one from each parent. […] If you inherit only one affected gene, you won’t develop MCAD deficiency, but you are a carrier and can pass the abnormal gene to your children. But they wouldn’t develop the condition unless they also inherited an affected gene from their other parent.

• #13 Medium chain acyl-CoA dehydrogenase deficiency (MCADD)

  https://www.medicalnewstoday.com/articles/medium-chain-acyl-coa-dehydrogenase-deficiency

  MCADD occurs due to a genetic difference in the ACADM gene, which stops the body from producing enough of the MCAD enzyme. […] MCADD is an autosomal recessive disorder, which means that both birth parents must pass the gene to a child for the child to have the condition. […] If someone receives one atypical gene and one working gene, they will not have MCADD themselves, but they may pass the gene to their own child.

• #14 Medium-Chain Acyl-CoA Dehydrogenase Deficiency – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560837/

  Mutations in the ACADM gene on chromosome 1p31 are responsible for this disorder. These mutations result in misfolding of the translated protein, leading to decreased or absent function of the MCAD enzyme. The ACADM gene spans 44kb of DNA and has 12 introns. Current data reports 400 different ACADM gene variations, of which 68 different variations have been classified as pathogenic, 82 variations as likely pathogenic, and around 165 variations grouped as „uncertain.” Around 69% of these disease-causing variations are missense mutations. […] The most prevalent mutation is c.985AG, resulting in lysine at position 304 being exchanged for glutamate. Misfolding of the protein subsequently occurs, leading to a complete loss of function. This mutation is the most common mutation in symptomatic patients, seen in up to 80% of the individuals as a homozygous mutation. It may also occur in heterozygosity with other variants, resulting in a milder form of the disease. […] MCADD is an autosomal recessive disorder caused by mutations in the acyl-CoA dehydrogenase medium chain (ACADM) gene.

• #15 Medium-Chain Acyl-CoA Dehydrogenase Deficiency – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560837/

  Mutations in the ACADM gene on chromosome 1p31 are responsible for this disorder. These mutations result in misfolding of the translated protein, leading to decreased or absent function of the MCAD enzyme. The ACADM gene spans 44kb of DNA and has 12 introns. Current data reports 400 different ACADM gene variations, of which 68 different variations have been classified as pathogenic, 82 variations as likely pathogenic, and around 165 variations grouped as „uncertain.” Around 69% of these disease-causing variations are missense mutations. […] The most prevalent mutation is c.985AG, resulting in lysine at position 304 being exchanged for glutamate. Misfolding of the protein subsequently occurs, leading to a complete loss of function. This mutation is the most common mutation in symptomatic patients, seen in up to 80% of the individuals as a homozygous mutation. It may also occur in heterozygosity with other variants, resulting in a milder form of the disease. […] MCADD is an autosomal recessive disorder caused by mutations in the acyl-CoA dehydrogenase medium chain (ACADM) gene.

• #16 Medium-chain acyl-coenzyme A dehydrogenase deficiency – Wikipedia

  https://en.wikipedia.org/wiki/Medium-chain_acyl-coenzyme_A_dehydrogenase_deficiency

  Medium-chain acyl-CoA dehydrogenase deficiency (MCAD deficiency or MCADD) is a disorder of fatty acid oxidation that impairs the body’s ability to break down medium-chain fatty acids into acetyl-CoA. […] MCADD is inherited in an autosomal recessive manner, meaning an affected individual must inherit a mutated allele from both of their parents. […] There is a common mutation among Northern European Caucasians, replacement of an adenine at position 985 with guanine, which results in a substitution of lysine with glutamic acid at position 304 of the protein. […] An individual’s genotype does not correlate well with their clinical phenotype for MCADD. […] Despite this, treatment with fasting avoidance remains the norm for all those diagnosed with MCADD. […] MCADD is most prevalent in individuals of Northern European Caucasian descent. The incidence in Northern Germany is 1:4000, currently the highest in the world.

• #17 Orphanet: Medium chain acyl-CoA dehydrogenase deficiency

  https://www.orpha.net/en/disease/detail/42

  MCADD is caused by mutations in the ACADM gene (1p31) which encodes the mitochondrial MCAD protein. The most prevalent mutation, c.985AG, (K329E), p.(Lys329Glu), accounted for about 80% of clinical disease prior to newborn screening programs but many more individuals are now being identified with other ACADM mutations. […] The estimated birth prevalence of MCADD is thought to range from 1/4,900 to 1/27,000 in Caucasian populations and is highest in individuals of Northern European descent. The worldwide birth prevalence is 1/14,600.

• #18 Medium-chain acyl-CoA dehydrogenase deficiency – Genomics Education Programme

  http://www.genomicseducation.hee.nhs.uk/documents/medium-chain-acyl-coa-dehydrogenase-deficiency/

  Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is an autosomal recessive disorder of fatty acid oxidation that prevents the conversion of fats to energy via hepatic ketogenesis. This impairs the supply of energy to peripheral tissues, causing a continual reliance on glucose to provide energy. […] MCADD is caused by autosomal recessive variants in the ACADM gene, which encodes the mitochondrial medium-chain acyl-CoA dehydrogenase (MCAD) enzyme. […] The most prevalent variant is c.985AG, which accounts for 80% of cases. […] Other variants, for example, p.Tyr42His (which has an allele frequency of ~6%) are associated with some residual MCAD enzyme activity. However, individuals with this phenotype can still develop life-threatening symptoms in an acute crisis.

• #19 Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency (MCADD) Clinical Presentation: History, Physical, Causes

  https://emedicine.medscape.com/article/946755-clinical

  The gene has been mapped to locus 1p31; more than 80 allelic variations have been reported. The most common mutation is 985AG, which refers to a substitution of a guanine nucleotide for an adenine nucleotide at the 985th residue. A second mutation, 583GA, is reportedly common in certain populations. One study reported that individuals homozygous for 985AG or 583GA mutations had the highest levels of octanoylcarnitine, even when asymptomatic, and had the most severe clinical manifestations. This has not been confirmed to date. […] Acute hepatic failure in a previously healthy gravid female who is homozygous for the 985AG mutation has been reported, thus confirming the potential for later onset, as well as the severity of complications with this specific mutation.

• #20 A novel mutation of the ACADM gene (c.145C>G) associated with the common c.985A>G mutation on the other ACADM allele causes mild MCAD deficiency: a case report | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-5-26

  A female patient, with normal familial history, developed at the age of 30 months an episode of diarrhoea, vomiting and lethargy which resolved spontaneously. […] Genetic studies showed that the patient was compound heterozygous with a sequence variation in both of the two ACADM alleles; one had the common c.985AG mutation and the other had a novel c.145CG mutation. […] This is the first report for the ACADM gene c.145CG mutation: it is located in exon 3 and causes a replacement of glutamine to glutamate at position 24 of the mature protein (Q24E). Associated with heterozygosity for c.985AG mutation, this mutation is responsible for a mild MCADD phenotype along with a clinical story corroborating the emerging literature view that patients with genotypes representing mild MCADD (high residual enzyme activity and low urinary levels of glycine conjugates), similar to some of the mild MCADDs detected by MS/MS newborn screening, may be at risk for disease presentation.

• #21 Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1424/

  Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency is a disorder of mitochondrial fatty acid beta-oxidation. […] MCAD deficiency is inherited in an autosomal recessive manner. […] The leading 25 amino acids of the precursor protein are cleaved off once the MCAD protein has reached the mitochondria. […] Individuals with MCAD deficiency have reduced mitochondrial MCAD enzyme functioning and cannot convert medium-chain fatty acids (those with 6-10 carbons) into acetyl-CoA for ATP synthesis, ketogenesis, and Krebs (i.e., tricarboxylic acid) cycle use. […] Loss of function.

• #22 Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency (MCADD): Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/946755-overview

  The pathophysiology of MCAD deficiency results from the inability to carry out the first step of beta-oxidation. The molecular implication of most mutations in this disorder is a loss of enzymatic function due to protein misfolding; the amino acid substitutions secondary to the genetic mutations impairs the acquisition of a normal 3-dimensional shape. […] Any clinical situation in which fatty acid oxidation is required, such as fasting or metabolic stress due to illness, results in continued glucose consumption and a markedly reduced or absent corresponding increase in ketone body production. […] A 2016 study has suggested that metabolic stress causing flooding of the -oxidative pathway with substrate may contribute to competitive inhibition, thus enhancing metabolic decompensation. […] The ultimate clinical result is severe hypoglycemia and hypoketonuria with accumulation of monocarboxylic fatty acids and dicarboxylic organic acids, which are structural analogues of the fatty acids that cannot pass through the MCAD step.

• #23 Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency (MCADD): Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/946755-overview

  The pathophysiology of MCAD deficiency results from the inability to carry out the first step of beta-oxidation. The molecular implication of most mutations in this disorder is a loss of enzymatic function due to protein misfolding; the amino acid substitutions secondary to the genetic mutations impairs the acquisition of a normal 3-dimensional shape. […] Any clinical situation in which fatty acid oxidation is required, such as fasting or metabolic stress due to illness, results in continued glucose consumption and a markedly reduced or absent corresponding increase in ketone body production. […] A 2016 study has suggested that metabolic stress causing flooding of the -oxidative pathway with substrate may contribute to competitive inhibition, thus enhancing metabolic decompensation. […] The ultimate clinical result is severe hypoglycemia and hypoketonuria with accumulation of monocarboxylic fatty acids and dicarboxylic organic acids, which are structural analogues of the fatty acids that cannot pass through the MCAD step.

• #24 Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency (MCADD): Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/946755-overview

  The pathophysiology of MCAD deficiency results from the inability to carry out the first step of beta-oxidation. The molecular implication of most mutations in this disorder is a loss of enzymatic function due to protein misfolding; the amino acid substitutions secondary to the genetic mutations impairs the acquisition of a normal 3-dimensional shape. […] Any clinical situation in which fatty acid oxidation is required, such as fasting or metabolic stress due to illness, results in continued glucose consumption and a markedly reduced or absent corresponding increase in ketone body production. […] A 2016 study has suggested that metabolic stress causing flooding of the -oxidative pathway with substrate may contribute to competitive inhibition, thus enhancing metabolic decompensation. […] The ultimate clinical result is severe hypoglycemia and hypoketonuria with accumulation of monocarboxylic fatty acids and dicarboxylic organic acids, which are structural analogues of the fatty acids that cannot pass through the MCAD step.

• #25 Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency (MCADD): Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/946755-overview

  These dicarboxylic acids include adipic (C6), suberic (C8), sebacic (C10), and dodecanedioic (C12). […] Octanoic acid (a C8 fatty acid), which accumulates during an impending metabolic decompensation in an affected patient, is a well-known mitochondrial toxin; this may account for the disruption of ammonia metabolism that often accompanies the clinical presentation of MCAD deficiency. […] Finally, gluconeogenesis is effectively disabled in MCAD deficiency because it depends on the activity of pyruvate carboxylase to produce oxaloacetate, a reaction that is downregulated by diminished mitochondrial acetyl-CoA.

• #26 Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency (MCADD): Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/946755-overview

  These dicarboxylic acids include adipic (C6), suberic (C8), sebacic (C10), and dodecanedioic (C12). […] Octanoic acid (a C8 fatty acid), which accumulates during an impending metabolic decompensation in an affected patient, is a well-known mitochondrial toxin; this may account for the disruption of ammonia metabolism that often accompanies the clinical presentation of MCAD deficiency. […] Finally, gluconeogenesis is effectively disabled in MCAD deficiency because it depends on the activity of pyruvate carboxylase to produce oxaloacetate, a reaction that is downregulated by diminished mitochondrial acetyl-CoA.

• #27 MCADD

  https://www.nhs.uk/conditions/mcadd/

  MCADD is caused by a fault in the gene that provides the instructions to make an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). […] This genetic fault causes the enzyme to either not work properly or be missing entirely, which means the body cannot fully break down fat to release energy. […] If the body needs to break down fat quickly (for example, if you’re unwell and have not eaten for a while), energy cannot be produced quickly enough to meet the body’s needs and substances created when fat is partially broken down can build up to harmful levels in the body. […] This can lead to serious problems if not treated quickly.

• #28

  https://www.gov.uk/government/publications/family-history-of-mcadd-information-sheet/mcadd-the-importance-of-taking-a-family-history

  Babies with a family history of medium-chain acyl-CoA dehydrogenase deficiency (MCADD) may require additional care. […] It is always important to establish whether there is a family history of MCADD so that timely action can be taken. […] If a mother or her partner has a family history of MCADD you should make a referral to a paediatrician or genetic counsellor for advice. […] Depending on the risk of the baby having MCADD, the parents may be advised that their baby needs early screening for MCADD. […] During long periods between eating, the body breaks down its own fat stores to produce energy. People with this inherited condition MCADD lack one of the enzymes needed to do this. […] They can break down the stored fat partly but not completely. […] There is a hold up at the medium-chain fat step where the enzyme needed to complete the breakdown is not working properly.

• #29

  https://111.wales.nhs.uk/encyclopaedia/m/article/mcadd/

  MCADD is caused by a fault in the gene that provides the instructions to make an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). […] This genetic fault causes the enzyme to either not work properly or be missing entirely, which means the body cannot fully break down fat to release energy. […] If the body needs to break down fat quickly (for example, if you’re unwell and have not eaten for a while), energy cannot be produced quickly enough to meet the body’s needs and substances created when fat is partially broken down can build up to harmful levels in the body. […] A child will only be born with MCADD if they inherit a copy of the faulty gene that causes it from both of their parents. […] The parents will not normally have the condition themselves because they usually only have one copy of the faulty gene each. This is known as being a „carrier”.

• #30 MCADD – Inherited Metabolic Disorders in Scotland

  https://www.imd.scot.nhs.uk/mcadd/

  Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a rare but treatable inherited disorder. […] Babies with MCADD have inherited two faulty copies of the gene for MCADD, one from each parent. […] MCADD only causes problems when fats need to be broken down quickly for example if a baby has not eaten for a long period or if they have an infection. […] Causes of a metabolic crisis can include an infection such as a stomach upset or vomiting illness.

• #31 The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update | Genetics in Medicine

  https://www.nature.com/articles/gim200638

  The overall mortality rate among all children with MCADD is necessarily lower than that among those who experience metabolic crises, because a fraction of individuals with the disorder do not manifest signs and symptoms in childhood. […] The frequency of deaths among older siblings of children with MCADD seems elevated relative to that among probands. […] The reduced ability to metabolize medium-chain fatty acids becomes problematic when individuals are faced with extra metabolic demands or reduced dietary inputs. Most often, stress induced by fasting or infection, during which the demands on fatty acid oxidation are particularly high, leads to symptomatic presentation. […] It is widely believed that adverse outcomes in MCADD can largely be prevented through avoidance of fasting, along with close attention by parents and clinicians during periods of infection and after immunizations.

• #32

  https://www.gov.uk/government/publications/family-history-of-mcadd-information-sheet/mcadd-the-importance-of-taking-a-family-history

  This causes a build-up of medium-chain fats. […] Sometimes there is a need to break down fats quickly, for example when there is an extended period of not eating or when there is an infection. […] People with MCADD cant do this. […] The medium-chain fats can build up and make toxic substances that may lead to serious symptoms. […] If this condition is not diagnosed early or is ignored and not treated by following simple advice from a specialist medical team, it could lead to serious illness and possibly death.

• #33 MCADD – Inherited Metabolic Disorders in Scotland

  https://www.imd.scot.nhs.uk/mcadd/

  Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a rare but treatable inherited disorder. […] Babies with MCADD have inherited two faulty copies of the gene for MCADD, one from each parent. […] MCADD only causes problems when fats need to be broken down quickly for example if a baby has not eaten for a long period or if they have an infection. […] Causes of a metabolic crisis can include an infection such as a stomach upset or vomiting illness.

• #34 Newborn Bloodspot Screening – Your baby’s screening result – Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is suspected – Public Health Wales

  https://phw.nhs.wales/services-and-teams/screening/newborn-bloodspot-screening-wales/information-resources/leaflets/information-for-parents/mcadd-is-suspected1/

  Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a rare but treatable inherited disorder. […] Babies with MCADD inherit two faulty copies of the gene for MCADD, one from each parent. […] Babies with MCADD have a problem breaking down fats quickly enough to produce energy. […] MCADD only causes problems when fats need to be broken down quickly, for example when a baby has not eaten for a long period or when they are unwell. […] If this happens, MCADD can cause low blood sugar and a build-up of certain fats. […] Without early diagnosis and treatment, MCADD can lead to serious illness and possibly death.

• #35 MCAD Deficiency: Symptoms, Causes, Treatment | Qwark

  https://qwarkhealth.com/conditions/mcad-deficiency?srsltid=AfmBOorbtsa2qzEQ9e84PtIxPEh10tEI4fKLH8UjI2v6iMe5ir_vV8Am

  MCAD deficiency is caused by a mutation in the ACADM gene, which provides instructions for making the MCAD enzyme. This enzyme is responsible for breaking down medium-chain fatty acids as an energy source. If the enzyme is not functioning correctly or is absent altogether, the body cannot use these fatty acids for energy, which can result in low blood sugar levels and an overproduction of certain acids in the body. […] The genetic factors that contribute to MCAD deficiency are mutations in the ACADM gene. These mutations can be inherited from one or both parents, and they can be either homozygous or heterozygous. Homozygous mutations mean that an individual has two copies of the ACADM gene with the mutation, while heterozygous mutations mean that an individual has one normal copy of the gene and one copy with the mutation. […] MCAD deficiency is not typically caused by external factors but is instead a genetic disorder. However, certain factors can trigger symptoms in individuals with MCAD deficiency, such as fasting, illness, and heavy physical activity.

• #36

  https://www.gov.uk/government/publications/family-history-of-mcadd-information-sheet/mcadd-the-importance-of-taking-a-family-history

  This causes a build-up of medium-chain fats. […] Sometimes there is a need to break down fats quickly, for example when there is an extended period of not eating or when there is an infection. […] People with MCADD cant do this. […] The medium-chain fats can build up and make toxic substances that may lead to serious symptoms. […] If this condition is not diagnosed early or is ignored and not treated by following simple advice from a specialist medical team, it could lead to serious illness and possibly death.

• #37 MCADD – Cavalier Matters

  https://www.cavaliermatters.org/mcadd-medium-chain-acyl-coa-dehydrogenase-deficiency/

  MCADD is caused by a fault in the gene that provides the instructions to make an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). This genetic fault causes the enzyme to either not work properly or be missing entirely, which means the body cannot fully break down fat to release energy. […] MCADD can lead to hypoglycaemia, which may cause weakness, shakiness, disorientation, and even seizures.

• #38 Medium chain acyl-CoA dehydrogenase deficiency (MCADD) – GPnotebook

  https://gpnotebook.com/pages/oncology/medium-chain-acyl-coa-dehydrogenase-deficiency-mcadd

  Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is an autosomal recessive inherited metabolic disease which is a known treatable cause of sudden infant death. […] MCADD results from the lack of an enzyme required to convert fat to energy. […] MCADD causes no apparent symptoms at birth, but low blood sugar, seizures, brain damage, heart failure and serious illness can occur very quickly in infants who are not feeding well.

• #39 SciELO Brazil – Medium Chain Acyl CoA Dehydrogenase Deficiency and Eating Disorders: An Underreported Coincidence Medium Chain Acyl CoA Dehydrogenase Deficiency and Eating Disorders: An Underreported Coincidence

  https://www.scielo.br/j/jiems/a/5CCSBv6vW4LtKwSWCS35sRv/

  Phenotypic heterogeneity in MCADD is also apparent, with some patients more prone to metabolic decompensation than others. […] The management of MCADD and many other inborn errors of metabolism necessitates a prescriptive diet from the time of diagnosis. […] The development of obesity is a risk for patients with MCADD, presumably owing to the reiteration of recommendations to avoid fasting and increase carbohydrate intake, particularly when unwell. […] Despite these aspects of management, there are minimal reports of the prevalence and a low awareness of eating disorders in MCADD patients. […] Mortality of up to 50% has been reported in undiagnosed patients presenting with an acute metabolic decompensation highlight the significance of this disorder. […] These cases suggest that eating disorders should be considered in the routine assessment of MCADD patients especially during adolescence and young adulthood. […] Disordered eating is likely more common than currently recognised in patients with metabolic disorders such as MCADD, which predisposes these patients to metabolic decompensation.

• #40 Medium-chain acyl-coenzyme A dehydrogenase deficiency – Wikipedia

  https://en.wikipedia.org/wiki/Medium-chain_acyl-coenzyme_A_dehydrogenase_deficiency

  Medium-chain acyl-CoA dehydrogenase deficiency (MCAD deficiency or MCADD) is a disorder of fatty acid oxidation that impairs the body’s ability to break down medium-chain fatty acids into acetyl-CoA. […] MCADD is inherited in an autosomal recessive manner, meaning an affected individual must inherit a mutated allele from both of their parents. […] There is a common mutation among Northern European Caucasians, replacement of an adenine at position 985 with guanine, which results in a substitution of lysine with glutamic acid at position 304 of the protein. […] An individual’s genotype does not correlate well with their clinical phenotype for MCADD. […] Despite this, treatment with fasting avoidance remains the norm for all those diagnosed with MCADD. […] MCADD is most prevalent in individuals of Northern European Caucasian descent. The incidence in Northern Germany is 1:4000, currently the highest in the world.

• #41 Medium-chain acyl-coenzyme A dehydrogenase deficiency – Wikipedia

  https://en.wikipedia.org/wiki/Medium-chain_acyl-coenzyme_A_dehydrogenase_deficiency

  Medium-chain acyl-CoA dehydrogenase deficiency (MCAD deficiency or MCADD) is a disorder of fatty acid oxidation that impairs the body’s ability to break down medium-chain fatty acids into acetyl-CoA. […] MCADD is inherited in an autosomal recessive manner, meaning an affected individual must inherit a mutated allele from both of their parents. […] There is a common mutation among Northern European Caucasians, replacement of an adenine at position 985 with guanine, which results in a substitution of lysine with glutamic acid at position 304 of the protein. […] An individual’s genotype does not correlate well with their clinical phenotype for MCADD. […] Despite this, treatment with fasting avoidance remains the norm for all those diagnosed with MCADD. […] MCADD is most prevalent in individuals of Northern European Caucasian descent. The incidence in Northern Germany is 1:4000, currently the highest in the world.

• #42 A novel mutation of the ACADM gene (c.145C>G) associated with the common c.985A>G mutation on the other ACADM allele causes mild MCAD deficiency: a case report | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-5-26

  Recent work, however, suggests that the link between susceptibility to develop metabolic decompensation and MCADD patient genotype is not straightforward and that this susceptibility is largely dependent on environmental triggers such as starvation stress, infection and/or fever. […] To our knowledge, this is the first report for the c.145 CG mutation in the ACADM gene. […] As a general rule, amino acid changes introduced in a mature protein affect its conformation and this may impact its final stability and function/activity. […] The Q24E variant has not been previously described. The amino acid change here occurs in the MCAD N-terminal domain. Some of the protein variants with mutations in this protein region may present with normal or close to normal enzyme activity.

• #43 SciELO Brazil – Medium Chain Acyl CoA Dehydrogenase Deficiency and Eating Disorders: An Underreported Coincidence Medium Chain Acyl CoA Dehydrogenase Deficiency and Eating Disorders: An Underreported Coincidence

  https://www.scielo.br/j/jiems/a/5CCSBv6vW4LtKwSWCS35sRv/

  Medium chain acyl-coA dehydrogenase deficiency (MCADD) is the most common disorder of fatty acid oxidation with a varied prevalence depending on ethnicity. […] MCADD is an autosomal recessively inherited condition due to genetic mutations in the ACADM gene on chromosome 1p31, which codes for the enzyme responsible for medium chain fatty acid catabolism. The most common associated genotype is a homozygous missense mutation of 985AG in ACADM, which results in lysine being substituted for glutamic acid in the protein in position 304 (p.Lys304Glu); this is found in approximately 80% of patients. […] Most cases of MCADD are currently diagnosed through newborn screening programs, with the introduction of this disorder into screening panels in 2005 in Western Australia. […] Patients with MCADD are at risk of several life-threatening issues should they develop metabolic decompensation.

• #44 The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update | Genetics in Medicine

  https://www.nature.com/articles/gim200638

  The most common fatty acid oxidation disorder, medium chain acyl-CoA dehydrogenase deficiency (MCADD), has become the focal point for the adoption of tandem mass spectrometry to detect it and related inborn errors of metabolism. […] MCADD is a mitochondrial fatty acid oxidation disorder that results from inactivity or deficiency of the medium chain acyl-CoA dehydrogenase (MCAD) protein. The MCAD protein is an enzyme that catalyzes the beta-oxidation of fatty acids. This process is critical to the formation of ketone bodies in the liver, which provide an alternative energy source during periods of prolonged fasting or increased energy demands. […] The calculated mortality risk in MCADD depends on the length of follow-up, because deaths associated with the disorder can occur through at least 3 years of age.

• #45 Orphanet: Medium chain acyl-CoA dehydrogenase deficiency

  https://www.orpha.net/en/disease/detail/42

  MCADD is caused by mutations in the ACADM gene (1p31) which encodes the mitochondrial MCAD protein. The most prevalent mutation, c.985AG, (K329E), p.(Lys329Glu), accounted for about 80% of clinical disease prior to newborn screening programs but many more individuals are now being identified with other ACADM mutations. […] The estimated birth prevalence of MCADD is thought to range from 1/4,900 to 1/27,000 in Caucasian populations and is highest in individuals of Northern European descent. The worldwide birth prevalence is 1/14,600.

• #46 Orphanet: Medium chain acyl-CoA dehydrogenase deficiency

  https://www.orpha.net/en/disease/detail/42

  MCADD is caused by mutations in the ACADM gene (1p31) which encodes the mitochondrial MCAD protein. The most prevalent mutation, c.985AG, (K329E), p.(Lys329Glu), accounted for about 80% of clinical disease prior to newborn screening programs but many more individuals are now being identified with other ACADM mutations. […] The estimated birth prevalence of MCADD is thought to range from 1/4,900 to 1/27,000 in Caucasian populations and is highest in individuals of Northern European descent. The worldwide birth prevalence is 1/14,600.

• #47 Medium-chain acyl-coenzyme A dehydrogenase deficiency – Wikipedia

  https://en.wikipedia.org/wiki/Medium-chain_acyl-coenzyme_A_dehydrogenase_deficiency

  Medium-chain acyl-CoA dehydrogenase deficiency (MCAD deficiency or MCADD) is a disorder of fatty acid oxidation that impairs the body’s ability to break down medium-chain fatty acids into acetyl-CoA. […] MCADD is inherited in an autosomal recessive manner, meaning an affected individual must inherit a mutated allele from both of their parents. […] There is a common mutation among Northern European Caucasians, replacement of an adenine at position 985 with guanine, which results in a substitution of lysine with glutamic acid at position 304 of the protein. […] An individual’s genotype does not correlate well with their clinical phenotype for MCADD. […] Despite this, treatment with fasting avoidance remains the norm for all those diagnosed with MCADD. […] MCADD is most prevalent in individuals of Northern European Caucasian descent. The incidence in Northern Germany is 1:4000, currently the highest in the world.

• #48 Diseases

  https://www.neoscreening.ch/en/diseases/

  MCADD is a congenital disorder affecting the breakdown of fatty acids in adipose tissue. […] If undiagnosed, the first onset frequently leads to death. […] However, if appropriate preventative measures are taken (avoiding long periods of fasting and providing a sufficient intake of carbohydrates, especially during infections with fever) the prognosis is excellent. MCADD affects one in 10,000 newborns.

• #49 The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update | Genetics in Medicine

  https://www.nature.com/articles/gim200638

  The most common fatty acid oxidation disorder, medium chain acyl-CoA dehydrogenase deficiency (MCADD), has become the focal point for the adoption of tandem mass spectrometry to detect it and related inborn errors of metabolism. […] MCADD is a mitochondrial fatty acid oxidation disorder that results from inactivity or deficiency of the medium chain acyl-CoA dehydrogenase (MCAD) protein. The MCAD protein is an enzyme that catalyzes the beta-oxidation of fatty acids. This process is critical to the formation of ketone bodies in the liver, which provide an alternative energy source during periods of prolonged fasting or increased energy demands. […] The calculated mortality risk in MCADD depends on the length of follow-up, because deaths associated with the disorder can occur through at least 3 years of age.

• #50 The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update | Genetics in Medicine

  https://www.nature.com/articles/gim200638

  The overall mortality rate among all children with MCADD is necessarily lower than that among those who experience metabolic crises, because a fraction of individuals with the disorder do not manifest signs and symptoms in childhood. […] The frequency of deaths among older siblings of children with MCADD seems elevated relative to that among probands. […] The reduced ability to metabolize medium-chain fatty acids becomes problematic when individuals are faced with extra metabolic demands or reduced dietary inputs. Most often, stress induced by fasting or infection, during which the demands on fatty acid oxidation are particularly high, leads to symptomatic presentation. […] It is widely believed that adverse outcomes in MCADD can largely be prevented through avoidance of fasting, along with close attention by parents and clinicians during periods of infection and after immunizations.

• #51 The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update | Genetics in Medicine

  https://www.nature.com/articles/gim200638

  The overall mortality rate among all children with MCADD is necessarily lower than that among those who experience metabolic crises, because a fraction of individuals with the disorder do not manifest signs and symptoms in childhood. […] The frequency of deaths among older siblings of children with MCADD seems elevated relative to that among probands. […] The reduced ability to metabolize medium-chain fatty acids becomes problematic when individuals are faced with extra metabolic demands or reduced dietary inputs. Most often, stress induced by fasting or infection, during which the demands on fatty acid oxidation are particularly high, leads to symptomatic presentation. […] It is widely believed that adverse outcomes in MCADD can largely be prevented through avoidance of fasting, along with close attention by parents and clinicians during periods of infection and after immunizations.

• #52 SciELO Brazil – Medium Chain Acyl CoA Dehydrogenase Deficiency and Eating Disorders: An Underreported Coincidence Medium Chain Acyl CoA Dehydrogenase Deficiency and Eating Disorders: An Underreported Coincidence

  https://www.scielo.br/j/jiems/a/5CCSBv6vW4LtKwSWCS35sRv/

  Phenotypic heterogeneity in MCADD is also apparent, with some patients more prone to metabolic decompensation than others. […] The management of MCADD and many other inborn errors of metabolism necessitates a prescriptive diet from the time of diagnosis. […] The development of obesity is a risk for patients with MCADD, presumably owing to the reiteration of recommendations to avoid fasting and increase carbohydrate intake, particularly when unwell. […] Despite these aspects of management, there are minimal reports of the prevalence and a low awareness of eating disorders in MCADD patients. […] Mortality of up to 50% has been reported in undiagnosed patients presenting with an acute metabolic decompensation highlight the significance of this disorder. […] These cases suggest that eating disorders should be considered in the routine assessment of MCADD patients especially during adolescence and young adulthood. […] Disordered eating is likely more common than currently recognised in patients with metabolic disorders such as MCADD, which predisposes these patients to metabolic decompensation.

• #53 SciELO Brazil – Medium Chain Acyl CoA Dehydrogenase Deficiency and Eating Disorders: An Underreported Coincidence Medium Chain Acyl CoA Dehydrogenase Deficiency and Eating Disorders: An Underreported Coincidence

  https://www.scielo.br/j/jiems/a/5CCSBv6vW4LtKwSWCS35sRv/

  Medium chain acyl-coA dehydrogenase deficiency (MCADD) is the most common disorder of fatty acid oxidation with a varied prevalence depending on ethnicity. […] MCADD is an autosomal recessively inherited condition due to genetic mutations in the ACADM gene on chromosome 1p31, which codes for the enzyme responsible for medium chain fatty acid catabolism. The most common associated genotype is a homozygous missense mutation of 985AG in ACADM, which results in lysine being substituted for glutamic acid in the protein in position 304 (p.Lys304Glu); this is found in approximately 80% of patients. […] Most cases of MCADD are currently diagnosed through newborn screening programs, with the introduction of this disorder into screening panels in 2005 in Western Australia. […] Patients with MCADD are at risk of several life-threatening issues should they develop metabolic decompensation.

• #54 Fatty Acid Oxidation Disorders – Children’s Health Issues – Merck Manual Consumer Version

  https://www.merckmanuals.com/home/children-s-health-issues/hereditary-metabolic-disorders/fatty-acid-oxidation-disorders

  Fatty acid oxidation disorders are lipid metabolism disorders that are caused by a lack or deficiency of the enzymes needed to break down fats, resulting in delayed mental and physical development. […] Fatty acid oxidation disorders occur when parents pass on to their children the defective genes that cause these disorders. […] In fatty acid oxidation disorders, both parents of the affected child carry 1 copy of the abnormal gene. […] The enzyme most commonly deficient is medium-chain acyl-CoA dehydrogenase (MCAD). […] Children who have a fatty acid oxidation disorder are missing or have a deficiency of the enzymes needed to break down (metabolize) fats. […] Symptoms of MCADD usually develop after 2 to 3 months of age. […] The long-term outcome is generally good.

• #55 Awareness Ribbon Causes Letter M | Personalized Cause

  https://www.personalizedcause.com/master-list-of-awareness-causes-m/?srsltid=AfmBOopAaMDxvoICbLon4739Lcf_u4b2YLXe_3ir81-RB6e2c7A4-02w

  Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD) is a genetic disorder caused by a lower than normal level of the medium chain acyl-coenzyme A dehydrogenase enzyme. […] Symptoms of this disorder generally develop between 1 and 24 months of age, although they can sometimes first appear in adulthood. […] Individuals with MCADD experience symptoms of metabolic crisis due to low blood sugar after periods of prolonged fasting or in response to a common illness.

• #56 Beta-Oxidation Cycle Disorders – Pediatrics – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/pediatrics/inherited-disorders-of-metabolism/beta-oxidation-cycle-disorders

  This deficiency is the most common defect in the beta-oxidation cycle. […] Clinical manifestations typically begin after 2 to 3 months of age and usually follow fasting (as little as 12 hours). […] Diagnosis of MCADD is by detecting medium-chain fatty acid conjugates of carnitine in plasma or glycine in urine or by detecting enzyme deficiency in cultured fibroblasts; however, DNA testing can confirm most cases. […] Treatment of acute attacks is with 10% dextrose IV at 1.5 times the fluid maintenance rate […] Prevention is a low-fat, high-carbohydrate diet and avoidance of prolonged fasting.

• #57 Awareness Ribbon Causes Letter M | Personalized Cause

  https://www.personalizedcause.com/master-list-of-awareness-causes-m/?srsltid=AfmBOopAaMDxvoICbLon4739Lcf_u4b2YLXe_3ir81-RB6e2c7A4-02w

  Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD) is a genetic disorder caused by a lower than normal level of the medium chain acyl-coenzyme A dehydrogenase enzyme. […] Symptoms of this disorder generally develop between 1 and 24 months of age, although they can sometimes first appear in adulthood. […] Individuals with MCADD experience symptoms of metabolic crisis due to low blood sugar after periods of prolonged fasting or in response to a common illness.

• #58 Medium chain acyl-CoA dehydrogenase deficiency (MCADD) – GPnotebook

  https://gpnotebook.com/pages/oncology/medium-chain-acyl-coa-dehydrogenase-deficiency-mcadd

  Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is an autosomal recessive inherited metabolic disease which is a known treatable cause of sudden infant death. […] MCADD results from the lack of an enzyme required to convert fat to energy. […] MCADD causes no apparent symptoms at birth, but low blood sugar, seizures, brain damage, heart failure and serious illness can occur very quickly in infants who are not feeding well.

• #59

  https://dhhr.wv.gov/ols/labs/Pages/fattyacidoxidationdisorders.aspx

  This disorder is caused by the lack of MCAD enzyme that breaks down fats stored in the body into sugars used to produce energy for bodily functions. […] Infants are usually asymptomatic but can go into shock or die suddenly if the infant has problems with feeding for more than 4 hours.

• #60 MCAD deficiency – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/mcad-deficiency/diagnosis-treatment/drc-20353747

  MCAD deficiency is diagnosed through newborn screening followed by genetic testing. […] Genetic testing can reveal the changed gene that causes MCAD deficiency. […] The main goal of treatment for MCAD deficiency is to prevent problems caused by your metabolism that can lead to low blood sugar. […] Parent and family understanding of the condition is critical to ongoing care and prevention of low blood sugar episodes and other complications. […] If you or your child have MCAD deficiency, wear a medical alert bracelet or necklace and carry a medical card. This lets health care providers know of your condition, even in an emergency.

• #61 MCAD deficiency – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/mcad-deficiency/diagnosis-treatment/drc-20353747

  MCAD deficiency is diagnosed through newborn screening followed by genetic testing. […] Genetic testing can reveal the changed gene that causes MCAD deficiency. […] The main goal of treatment for MCAD deficiency is to prevent problems caused by your metabolism that can lead to low blood sugar. […] Parent and family understanding of the condition is critical to ongoing care and prevention of low blood sugar episodes and other complications. […] If you or your child have MCAD deficiency, wear a medical alert bracelet or necklace and carry a medical card. This lets health care providers know of your condition, even in an emergency.

• #62 Blood spot tests in Scotland | NHS inform

  https://www.nhsinform.scot/healthy-living/screening/newborn-screening/blood-spot-test/

  Babies with MCADD deficiencies may have issues breaking down fat to make energy under certain circumstances. […] The blood sample will test for whether your baby has any of the following 6 inherited metabolic disorders: medium-chain acyl-CoA dehydrogenase deficiency (MCADD). […] Effective treatment is available to prevent the ill-effects of all 6 inherited metabolic disorders. This may include a carefully managed diet and/or medicines.

• #63 MCAD Deficiency Diagnosis and Treatment

  https://informnetwork.org/mcad-deficiency/

  Medium chain acyl-CoA dehydrogenase deficiency is an inherited disorder involving fat metabolism. MCAD deficiency occurs when an individual inherits one change (mutation) in the MCAD gene called ACADM from each parent. MCAD deficiency is unusual in that most affected people carry at least one copy of a specific common mutation that causes a change in the protein chain. In fact, 90% of those who inherit two ACADM mutations share one copy of this common mutation, and in approximately 70% of cases, those with MCAD deficiency have inherited this same common mutation from both parents. […] Genetic counseling can benefit affected individuals as well as their families.

• #64

  https://www.gov.uk/government/publications/family-history-of-mcadd-information-sheet/mcadd-the-importance-of-taking-a-family-history

  Babies with a family history of medium-chain acyl-CoA dehydrogenase deficiency (MCADD) may require additional care. […] It is always important to establish whether there is a family history of MCADD so that timely action can be taken. […] If a mother or her partner has a family history of MCADD you should make a referral to a paediatrician or genetic counsellor for advice. […] Depending on the risk of the baby having MCADD, the parents may be advised that their baby needs early screening for MCADD. […] During long periods between eating, the body breaks down its own fat stores to produce energy. People with this inherited condition MCADD lack one of the enzymes needed to do this. […] They can break down the stored fat partly but not completely. […] There is a hold up at the medium-chain fat step where the enzyme needed to complete the breakdown is not working properly.

• #65

  https://www.gov.uk/government/publications/family-history-of-mcadd-information-sheet/mcadd-the-importance-of-taking-a-family-history

  Babies with a family history of medium-chain acyl-CoA dehydrogenase deficiency (MCADD) may require additional care. […] It is always important to establish whether there is a family history of MCADD so that timely action can be taken. […] If a mother or her partner has a family history of MCADD you should make a referral to a paediatrician or genetic counsellor for advice. […] Depending on the risk of the baby having MCADD, the parents may be advised that their baby needs early screening for MCADD. […] During long periods between eating, the body breaks down its own fat stores to produce energy. People with this inherited condition MCADD lack one of the enzymes needed to do this. […] They can break down the stored fat partly but not completely. […] There is a hold up at the medium-chain fat step where the enzyme needed to complete the breakdown is not working properly.

• #66

  https://www.gov.uk/government/publications/family-history-of-mcadd-information-sheet/mcadd-the-importance-of-taking-a-family-history

  Babies with a family history of medium-chain acyl-CoA dehydrogenase deficiency (MCADD) may require additional care. […] It is always important to establish whether there is a family history of MCADD so that timely action can be taken. […] If a mother or her partner has a family history of MCADD you should make a referral to a paediatrician or genetic counsellor for advice. […] Depending on the risk of the baby having MCADD, the parents may be advised that their baby needs early screening for MCADD. […] During long periods between eating, the body breaks down its own fat stores to produce energy. People with this inherited condition MCADD lack one of the enzymes needed to do this. […] They can break down the stored fat partly but not completely. […] There is a hold up at the medium-chain fat step where the enzyme needed to complete the breakdown is not working properly.

• #67 MCAD Deficiency Diagnosis and Treatment

  https://informnetwork.org/mcad-deficiency/

  Medium chain acyl-CoA dehydrogenase deficiency is an inherited disorder involving fat metabolism. MCAD deficiency occurs when an individual inherits one change (mutation) in the MCAD gene called ACADM from each parent. MCAD deficiency is unusual in that most affected people carry at least one copy of a specific common mutation that causes a change in the protein chain. In fact, 90% of those who inherit two ACADM mutations share one copy of this common mutation, and in approximately 70% of cases, those with MCAD deficiency have inherited this same common mutation from both parents. […] Genetic counseling can benefit affected individuals as well as their families.

Zobacz więcej